Indian State FDA Calls For Probe Into ‘Exorbitant’ Stent Costs
This article was originally published in The Gray Sheet
Executive Summary
Cardiac stent makers are under the regulatory glare in India on allegations of exorbitant charges to patients. A state-level regulator is urging the national pricing watchdog to clamp down.